Literature DB >> 12869640

Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma.

Jonathan M Shipley1, David J Waxman.   

Abstract

The nuclear receptor peroxisome proliferator-activated receptor (PPAR) is activated by a diverse group of acidic ligands, including many peroxisome proliferator chemicals present in the environment. Janus tyrosine kinase-signal transducer and activator of transcription (JAK-STAT) signaling is activated by multiple cytokines and hormones and leads to the translocation of dimerized STAT proteins to the nucleus where they activate transcription of target genes. Previous studies have shown that growth hormone (GH)-activated STAT5b can inhibit PPAR-regulated transcription. Here, we show that this inhibitory cross-talk is mutual, and that GH-induced, STAT5b-dependent beta-casein promoter-luciferase reporter gene transcription can be inhibited up to approximately 80% by ligand-activated PPARalpha or PPARgamma. Dose-response experiments showed a direct relationship between the extent of PPAR activation and the degree of inhibition of STAT5-regulated transcription. PPAR did not block STAT5b tyrosine phosphorylation or inhibit DNA-binding activity. Both PPARs inhibited the transcriptional activity of a constitutively active STAT5b mutant, indicating that inhibition occurs downstream of the GH-stimulated STAT5 activation step. Transcriptionally inactive, dominant-negative PPAR mutants did not block STAT5b inhibition by wild-type PPAR, indicating that PPAR target gene transcription is not required. PPARalpha retained its STAT5b inhibitory activity in the presence of the histone deacetylase inhibitor trichostatin, indicating that enhanced histone deacetylase recruitment does not contribute to STAT5b inhibition. PPARalpha lacking the ligand-independent AF-1 trans-activation domain failed to inhibit STAT5b, highlighting the importance of the AF-1 region in STAT5-PPAR inhibitory cross-talk. These findings demonstrate the bidirectionality of cross-talk between the PPAR and STAT pathways and provide a mechanism whereby exposure to environmental chemical activators of PPAR can suppress expression of GH target genes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869640     DOI: 10.1124/mol.64.2.355

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  15 in total

Review 1.  PFAS and Potential Adverse Effects on Bone and Adipose Tissue Through Interactions With PPARγ.

Authors:  Andrea B Kirk; Stephani Michelsen-Correa; Cliff Rosen; Clyde F Martin; Bruce Blumberg
Journal:  Endocrinology       Date:  2021-12-01       Impact factor: 5.051

2.  Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b.

Authors:  Soo-Hee Park; Christopher A Wiwi; David J Waxman
Journal:  Biochem J       Date:  2006-07-01       Impact factor: 3.857

3.  Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis.

Authors:  David L M van der Meer; Tatjana Degenhardt; Sami Väisänen; Philip J de Groot; Merja Heinäniemi; Sacco C de Vries; Michael Müller; Carsten Carlberg; Sander Kersten
Journal:  Nucleic Acids Res       Date:  2010-01-27       Impact factor: 16.971

4.  Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators.

Authors:  Viola Tamasi; Kristy K Michael Miller; Sharon L Ripp; Ermin Vila; Thomas E Geoghagen; Russell A Prough
Journal:  Mol Pharmacol       Date:  2007-12-13       Impact factor: 4.436

5.  Alterations of renal phenotype and gene expression profiles due to protein overload in NOD-related mouse strains.

Authors:  Karen H S Wilson; Richard A McIndoe; Sarah Eckenrode; Laurence Morel; Anupam Agarwal; Byron P Croker; Jin-Xiong She
Journal:  BMC Nephrol       Date:  2005-12-21       Impact factor: 2.388

6.  Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.

Authors:  Veerle Reynders; Stefan Loitsch; Constanze Steinhauer; Thomas Wagner; Dieter Steinhilber; Joachim Bargon
Journal:  Respir Res       Date:  2006-07-30

7.  Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.

Authors:  Raquel Grau; Manuel D Díaz-Muñoz; Cristina Cacheiro-Llaguno; Manuel Fresno; Miguel A Iñiguez
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

8.  Loss of fibroblast growth factor 21 action induces insulin resistance, pancreatic islet hyperplasia and dysfunction in mice.

Authors:  W Y So; Q Cheng; A Xu; K S L Lam; P S Leung
Journal:  Cell Death Dis       Date:  2015-03-26       Impact factor: 8.469

9.  Increase of palmitic acid concentration impairs endothelial progenitor cell and bone marrow-derived progenitor cell bioavailability: role of the STAT5/PPARγ transcriptional complex.

Authors:  Antonella Trombetta; Gabriele Togliatto; Arturo Rosso; Patrizia Dentelli; Cristina Olgasi; Paolo Cotogni; Maria Felice Brizzi
Journal:  Diabetes       Date:  2012-12-06       Impact factor: 9.461

10.  Disruption of STAT5b-Regulated Sexual Dimorphism of the Liver Transcriptome by Diverse Factors Is a Common Event.

Authors:  Keiyu Oshida; Naresh Vasani; David J Waxman; J Christopher Corton
Journal:  PLoS One       Date:  2016-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.